Retinal Ganglion Cell Complex Changes by Optical Coherence Tomography in Diabetic Patients Without Retinopathy (RGCC)

December 1, 2015 updated by: Tamer Ahmed Macky, Cairo University

Retinal Ganglion Cell Complex Changes Using Spectral Domain Optical Coherence Tomography in Diabetic Patients Without Retinopathy

Neuroretinal damage in diabetes produces functional abnormalities such as the loss of chromatic discrimination,contrast sensitivity and dark adaptation. These alterations can be detected by means of electrophysiological studies in diabetic patients with diabetes duration of less than two years, i.e. before microvascular lesions can be detected in ophthalmologic examination. Neurodegeneration seems to be a generalized process that occurs throughout the macula and is not confined to local abnormalities, in the cases with visible signs of retinopathy.

The debate is still open as to whether diabetic retinal neuropathy is the effect of vascular diabetic retinopathy or is primarily caused by direct neurologic damage from chronic hyperglycemia. The hypothesis that diabetes causes retinal neuro-pathy independent of retinopathy is intriguing and potentially links retinal neuropathy to other diabetic neuropathies.

Neuroretinal degeneration initiates and/or activates several metabolic and signalling pathways which participates in the microangiopathic process as well as in the disruption of the blood-retinal barrier which is a crucial element in the pathogenesis of diabetic retinopathy.

Retinal ganglion cells are the earliest cells affected and have the highest rate of apoptosis. However, an elevated rate of apoptosis has been also observed in the outer nuclear layer (photoreceptors) and in the retinal pigment epithelium (RPE). The use of spectral domain OCT (SD-OCT) makes it possible to measure the thickness of individual layers at higher resolution and indicates that the thinning of the inner retina in the macula is primarily due to loss of ganglion cells.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This was a prospective case-control study conducted from October 2012 to April 2013 at Kasr Al-ainy hospital- cairo university.

The subjects were divided into two groups; Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). Group 2 consists of non-diabetic subjects, free from any ocular pathology(21 eyes).

All subjects were subjected to full medical and ophthalmological history, refraction, best corrected visual acuity (according to the snellen visual acuity chart and recorded in decimals), slit lamp examination (including measuring the intraocular pressure by Goldman applanation tonometer), dilated fundus examination by binocular indirect slit-lamp biomicroscopy and measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.) at the LASER unit, Kasr Al-ainy hospital.

In addition; diabetic patients were subjected to fundus fluorescein angiography to exclude diabetic changes that could be missed on clinical examination and measuring level of HbA1C in blood at kasr Al-ainy hospital chemical pathology unit.

Mapping of the GCC using the RTVue GCC scan consists of 15 vertical line scans covering a 7mm square region. The GCC scan centers at 1mm temporal to fovea center for better coverage of the temporal region.

The GCC thickness values are analyzed and compared to an extensive age-matched normative database. If the patient's values are outside the normal range, the measurement is color-coded appropriately. The Deviation Map shows the percent loss from normal as determined by the normative database. The significance Map shows regions where the change from normal reaches statistical significance. (Figure 1) Focal Loss Volume (FLV) and Global Loss Volume (GLV) are two parameters that provide quantitative measures for the amount of significant GCC loss. GLV measures the average amount of GCC loss over the entire GCC map. FLV measures the average amount of focal loss over the entire GCC map, it is the total sum of significant GCC loss (in volume) divided by the map area. As such it provides a percent of significant tissue loss for volume. FLV detects focal loss using a pattern deviation map to correct for overall absolute changes [5].

Statistical analysis included comparison of numerical variables between the study groups was done using Student t test for independent samples in normally distributed data and Mann Whitney U test for independent samples in non-normal data. For comparing categorical data, Chi square (2) test was performed. Exact test was used instead when the expected frequency is less than 5. Within group comparison between superior and inferior GCC was done using McNemar test. Agreement was tested using kappa statistic. Correlation between various variables was done using Spearman rank correlation equation. All statistical calculations were done using computer programs SPSS (Statistical Package for the Social Science; SPSS Inc., Chicago, IL, USA) version 15 for Microsoft Windows.

Study Type

Interventional

Enrollment (Actual)

35

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Cairo, Egypt, 11221
        • Department of Ophthalmology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Diabetic patients free from diabetic retinopathy will be group 1
  2. Non-diabetic subjects will be group 2.

Exclusion criteria included;

  1. Diabetic patients with diabetic retinopathy
  2. Patients having other ocular diseases as glaucoma or uveitis.
  3. Eye with history of previous ocular surgeries, trauma or intraocular injections or photocoagulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: G1 Diabetics with no retinpathy
Group 1 consists of diabetic patients free from diabetic retinopathy (45 eyes). OCT retinal GCC measurements.
Device: OCT Retinal GCC
measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
Other: G2 Non diabetics
Group consists of non-diabetic subjects, free from any ocular pathology(21 eyes).OCT retinal GCC measurements.
Device: OCT Retinal GCC
measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Retinal Ganglion Cell Complex in microns by Optical Coherence Tomography measurements
Time Frame: Baseline
Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Investigators

  • Study Chair: Soheir Esmat, MD PhD, Egypt:Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2013

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

December 1, 2014

Study Registration Dates

First Submitted

November 26, 2015

First Submitted That Met QC Criteria

December 1, 2015

First Posted (Estimate)

December 3, 2015

Study Record Updates

Last Update Posted (Estimate)

December 3, 2015

Last Update Submitted That Met QC Criteria

December 1, 2015

Last Verified

December 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Retinal GCC in Diabetics

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on OCT Retinal GCC

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe